TALEN

TALEN1-prnpb

ID

ZDB-TALEN-181112-2

Name

TALEN1-prnpb

Previous Names

None

Target

prnpb (1)

Target Sequence 1

5' - TTATGCAAACTTCTAGCC - 3'

Target Sequence 2

5' - TATAATGTAACACTGCCA - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
ua5003	prnpb
ua5004	prnpb

Expression

Gene expression in Wild Types + TALEN1-prnpb

No data available

Phenotype

Phenotype resulting from TALEN1-prnpb

No data available

Phenotype of all Fish created by or utilizing TALEN1-prnpb

Phenotype	Fish	Conditions	Figures
whole organism movement behavioral quality, exacerbated	prnpb^{ua5003/ua5003}	chemical treatment by environment: 2-methyl-6-(phenylethynyl)pyridine hydrochloride, chemical treatment by environment: pentetrazol	Fig. 5 from Kanyo et al., 2020
whole organism movement behavioral quality, abnormal	prnpb^{ua5003/ua5003}	chemical treatment by environment: pentetrazol	Fig. 4, Fig. 5 from Kanyo et al., 2020
swimming behavior disrupted, exacerbated	prnpb^{ua5003/ua5003}	chemical treatment by environment: pentetrazol	Fig. 4 from Kanyo et al., 2020
swimming behavior disrupted, exacerbated	prnpb^{ua5003/ua5003}	chemical treatment by environment: 2-methyl-6-(phenylethynyl)pyridine hydrochloride, chemical treatment by environment: pentetrazol	Fig. 5 from Kanyo et al., 2020
whole organism movement behavioral quality, exacerbated	prnpb^{ua5003/ua5003}	chemical treatment by environment: pentetrazol	Fig. 4 from Kanyo et al., 2020
swimming behavior disrupted, abnormal	prnpb^{ua5003/ua5003}	chemical treatment by environment: pentetrazol	Fig. 4, Fig. 5 from Kanyo et al., 2020
brain fosab expression increased amount, abnormal	prnpb^{ua5003/ua5003} (AB)	chemical treatment by environment: pentetrazol	Fig. S9 from Leighton et al., 2018
swimming behavior increased occurrence, exacerbated	prnpb^{ua5003/ua5003} (AB)	chemical treatment by environment: pentetrazol	Fig. 5 from Leighton et al., 2018
whole organism decreased length, abnormal	prnpb^{ua5003/ua5003} (AB)	standard conditions	Fig. 2 from Leighton et al., 2018
trunk neuromast decreased amount, abnormal	prnpb^{ua5004/ua5004} (AB)	standard conditions	Fig. 4 from Leighton et al., 2018
whole organism decreased length, abnormal	prnpb^{ua5004/ua5004} (AB)	standard conditions	Fig. 2 from Leighton et al., 2018
whole organism morphology, exacerbated	prnpb^{ua5003/ua5003} + MO2-appa (AB)	standard conditions	Fig. 3 from Kanyo et al., 2020
whole organism movement behavioral quality, exacerbated	appa^{ua5005/ua5005}; prnpb^{ua5003/ua5003} (AB)	chemical treatment by environment: pentetrazol	Fig. 4 from Kanyo et al., 2020
whole organism movement behavioral quality, ameliorated	appa^{ua5005/ua5005}; prnpb^{ua5003/ua5003} (AB)	chemical treatment by environment: pentetrazol	Fig. 5, Fig. S10 from Kanyo et al., 2020
swimming behavior disrupted, abnormal	appa^{ua5005/ua5005}; prnpb^{ua5003/ua5003} (AB)	chemical treatment by environment: pentetrazol	Fig. 4, Fig. S10 from Kanyo et al., 2020
whole organism decreased length, abnormal	appa^{ua5005/ua5005}; prnpb^{ua5003/ua5003} (AB)	standard conditions	Fig. S9 from Kanyo et al., 2020
whole organism movement behavioral quality, abnormal	appa^{ua5005/ua5005}; prnpb^{ua5003/ua5003} (AB)	chemical treatment by environment: pentetrazol	Fig. 4 from Kanyo et al., 2020
swimming behavior disrupted, exacerbated	appa^{ua5005/ua5005}; prnpb^{ua5003/ua5003} (AB)	chemical treatment by environment: pentetrazol	Fig. 4 from Kanyo et al., 2020
whole organism movement behavioral quality, ameliorated	appa^{ua5005/ua5005}; prnpb^{ua5003/ua5003} (AB)	chemical treatment by environment: 2-methyl-6-(phenylethynyl)pyridine hydrochloride, chemical treatment by environment: pentetrazol	Fig. 5 from Kanyo et al., 2020
hypothalamus posterior region fosab expression increased amount, abnormal	prnpb^{ua5003/ua5003}; prnprs3^{ua5001/ua5001}	chemical treatment by injection: amyloid-beta	Figure 5. from Özcan et al., 2020
whole organism st8sia2 expression decreased amount, abnormal	prnpb^{ua5003/ua5003}; prnprs3^{ua5001/ua5001}	standard conditions	Figure 2. from Pollock et al., 2021
dorsal telencephalon fosab expression increased amount, abnormal	prnpb^{ua5003/ua5003}; prnprs3^{ua5001/ua5001}	chemical treatment by injection: amyloid-beta	Figure 5. from Özcan et al., 2020
whole organism prnpb expression decreased amount, abnormal	prnpb^{ua5003/ua5003}; prnprs3^{ua5001/ua5001}	standard conditions	Figure 2. from Pollock et al., 2021
sleep decreased occurrence, exacerbated	prnpb^{ua5003/ua5003}; prnprs3^{ua5001/ua5001}	chemical treatment by injection: amyloid-beta	Figure 3 from Özcan et al., 2020
whole organism ncam1a expression decreased amount, abnormal	prnpb^{ua5003/ua5003}; prnprs3^{ua5001/ua5001}	standard conditions	Figure 2. from Pollock et al., 2021
whole organism prnprs3 expression decreased amount, abnormal	prnpb^{ua5003/ua5003}; prnprs3^{ua5001/ua5001}	standard conditions	Figure 2. from Pollock et al., 2021
locomotion decreased occurrence, abnormal	prnpb^{ua5003/ua5003}; prnprs3^{ua5001/ua5001} (AB)	standard conditions	Fig. 5 from Leighton et al., 2018
brain fosab expression increased amount, abnormal	prnpb^{ua5003/ua5003}; prnprs3^{ua5001/ua5001} (AB)	chemical treatment by environment: pentetrazol	Fig. S9 from Leighton et al., 2018
trunk neuromast amount, ameliorated	prnpb^{ua5003/ua5003}; prnprs3^{ua5001/ua5001} (AB)	standard conditions	Fig. 4 from Leighton et al., 2018
whole organism increased length, abnormal	prnpb^{ua5003/ua5003}; prnprs3^{ua5001/ua5001} (AB)	standard conditions	Fig. 3 from Leighton et al., 2018
locomotory behavior increased occurrence, ameliorated	prnpb^{ua5003/ua5003}; prnprs3^{ua5001/ua5001} (AB)	chemical treatment by environment: pentetrazol	Fig. 5 from Leighton et al., 2018
trunk neuromast amount, ameliorated	prnpb^{ua5004/ua5004}; prnprs3^{ua5001/ua5001} (AB)	standard conditions	Fig. 4 from Leighton et al., 2018

Citations